0001209191-23-020720.txt : 20230323 0001209191-23-020720.hdr.sgml : 20230323 20230323160522 ACCESSION NUMBER: 0001209191-23-020720 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230321 FILED AS OF DATE: 20230323 DATE AS OF CHANGE: 20230323 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hoerter Steven L. CENTRAL INDEX KEY: 0001533451 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 23756187 MAIL ADDRESS: STREET 1: C/O DECIPHERA PHARMACEUTICALS, INC. STREET 2: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001654151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200299725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-209-6400 MAIL ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC DATE OF NAME CHANGE: 20150928 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-03-21 0 0001654151 Deciphera Pharmaceuticals, Inc. DCPH 0001533451 Hoerter Steven L. C/O DECIPHERA PHARMACEUTICALS, INC. 200 SMITH STREET WALTHAM MA 02451 1 1 0 0 President and CEO 0 Common Stock 2023-03-21 4 S 0 7500 15.5709 D 0 D On March 18, 2019, the Reporting Person was granted 30,000 Restricted Stock Units ("RSUs") which vest in four (4) equal annual installments beginning on March 18, 2020. These RSUs were reported in Table I on a Form 4 filed on March 20, 2019. The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2022. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.395 to $15.70, inclusive. The Reporting Person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. /s/ Jeffrey M. Held, Attorney-in-Fact 2023-03-23